These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 23129543)

  • 21. Ventricular tachycardia or ventricular fibrillation occurs less often in patients with left bundle branch block and combined resynchronization and defibrillators than in patients with narrow QRS and conventional defibrillators.
    Blaschke F; Knaus T; Celebi O; Krebs A; Nitardy A; Habedank D; Dietz R; Stockburger M
    Europace; 2012 Feb; 14(2):224-9. PubMed ID: 21946820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients.
    Robin J; Weinberg K; Tiongson J; Carnethon M; Reddy M; Ciaccio C; Quadrini M; Hsu J; Fan J; Choi P; Kadish A; Goldberger J; Passman R
    Heart Rhythm; 2006 Oct; 3(10):1196-201. PubMed ID: 17018351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sleep-disordered breathing in recipients of implantable defibrillators.
    Grimm W; Sharkova J; Heitmann J; Jerrentrup A; Koehler U; Maisch B
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S8-11. PubMed ID: 19250118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.
    Wu KC; Gerstenblith G; Guallar E; Marine JE; Dalal D; Cheng A; Marbán E; Lima JA; Tomaselli GF; Weiss RG
    Circ Cardiovasc Imaging; 2012 Mar; 5(2):178-86. PubMed ID: 22267750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
    Klein G; Lissel C; Fuchs AC; Gardiwal A; Oswald H; Desousa M; Pichlmaier AM; Lichtinghagen R; Geerlings H; Lippolt P; Niehaus M; Drexler H; Korte T
    Europace; 2006 Aug; 8(8):618-24. PubMed ID: 16864615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT.
    Tompkins CM; McNitt S; Polonsky B; Daubert JP; Wang PJ; Moss AJ; Zareba W; Kutyifa V
    J Cardiovasc Electrophysiol; 2017 Jan; 28(1):94-102. PubMed ID: 27696593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Left ventricular scar burden specifies the potential for ventricular arrhythmogenesis: an LGE-CMR study.
    Scott PA; Rosengarten JA; Murday DC; Peebles CR; Harden SP; Curzen NP; Morgan JM
    J Cardiovasc Electrophysiol; 2013 Apr; 24(4):430-6. PubMed ID: 23210601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
    Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atrial fibrillation increases the risk of recurrent ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients.
    Rusnak J; Behnes M; Reiser L; Schupp T; Bollow A; Reichelt T; Borggrefe M; Ellguth D; Engelke N; El-Battrawy I; Ansari U; Barre M; Weidner K; Müller J; Barth C; Meininghaus DG; Akin M; Bertsch T; Taton G; Akin I
    Arch Cardiovasc Dis; 2021; 114(6-7):443-454. PubMed ID: 33967015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
    Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
    Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy.
    Fernández-Armenta J; Berruezo A; Mont L; Sitges M; Andreu D; Silva E; Ortiz-Pérez JT; Tolosana JM; de Caralt TM; Perea RJ; Calvo N; Trucco E; Borràs R; Matas M; Brugada J
    Europace; 2012 Nov; 14(11):1578-86. PubMed ID: 22562658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
    Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
    Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators.
    Brigadeau F; Kouakam C; Klug D; Marquié C; Duhamel A; Mizon-Gérard F; Lacroix D; Kacet S
    Eur Heart J; 2006 Mar; 27(6):700-7. PubMed ID: 16421175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and prognostic impact of comorbidities in heart failure patients with implantable cardioverter defibrillator.
    Bruch C; Bruch C; Sindermann J; Breithardt G; Gradaus R
    Europace; 2007 Aug; 9(8):681-6. PubMed ID: 17507354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.